PEN
Penumbra Inc Health Care Surgical & Medical Instruments & Apparatus Russell 3000
$318.95Close
$12.5BMarket cap
$225.54 – $359.4052-week range
Late-januaryNext report · estimated
Highlights
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Earnings shrinking EPS −9% year on year
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
11%
1wk
down 1.7%
price change
1mo
up 0.2%
price change
12-month return
up 38%
market up 11% ·
its own up 26%
F-score
8 / 9
Exceptional
Altman Z
20.79
Low risk
P/E
70.4×
price / earnings
PEG
0.06
P/E / EPS growth
P/B
8.8×
price / book
Earnings yield
up 1.5%
EBIT / enterprise value
Cheaper than
27%
of the market · expensive
Revenue growth
up 17%
year on year
EPS growth
down 9%
latest quarter · +15 pts
Sales growth
up 16%
latest quarter · +1 pts
ROE
up 14%
return on equity
Free cash margin
up 12%
$174.9M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-0.9×
net cash
Interest cover
—EBIT / interest
Piotroski tests
- issued more shares
- profitable on its assets
- generating cash from operations
- profitability improving
- profits backed by cash
- reduced long-term debt
- short-term liquidity improved
- gross margin widened
- assets working harder
Repair signals
- Gross margin 63.2% → 67.1%
Trade setup
ATR%
0.8%
$2.46 a day · 2×ATR $314.04
RS
51 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
1.4×
vs 50-day average
Up/down volume
0.87
50 sessions
Implied move
—
no scheduled report
Trend template · 3 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: fails
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: passes
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Oct 29, 2026
Results reaction
Oct 29, 2026+2% vs market2 sessions after results
Financials
- Gross 67%
- Net 13%
- Free cash 12%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $560.4M | $747.6M | $847.1M | $1.1B | $1.2B | $1.4B |
| Gross margin | 60% | 64% | 63% | 64% | 63% | 67% |
| Operating income | -$38.9M | -$7.5M | $6.1M | $73.6M | $9.3M | $189.2M |
| Net income | -$15.7M | $5.3M | -$2.0M | $91.0M | $14.0M | $177.7M |
| Net margin | -3% | 1% | -0% | 9% | 1% | 13% |
| Earnings per share | -$0.44 | $0.14 | -$0.05 | $2.32 | $0.36 | $4.52 |
| Free cash flow | -$58.0M | -$11.7M | -$75.0M | $82.1M | $147.3M | $174.9M |
| Free cash margin | -10% | -2% | -9% | 8% | 12% | 12% |
| Cash | $69.7M | $59.4M | $69.9M | $167.5M | $324.4M | $186.9M |
| Shareholders' equity | $641.5M | $953.9M | $998.9M | $1.2B | $1.2B | $1.4B |
| Shares outstanding | 36.41m | 37.58m | 38.11m | 38.68m | 38.49m | 39.23m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 29, 2026 | Quarterly ↗ | Sep 30, 2026 | 29d |
| Jul 30, 2026 | Quarterly ↗ | Jun 30, 2026 | 30d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Feb 25, 2026 | Annual ↗ | Dec 31, 2025 | 56d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Jul 29, 2025 | Quarterly ↗ | Jun 30, 2025 | 29d |
| Apr 23, 2025 | Quarterly ↗ | Mar 31, 2025 | 23d |
| Feb 18, 2025 | Annual ↗ | Dec 31, 2024 | 49d |
| Oct 30, 2024 | Quarterly ↗ | Sep 30, 2024 | 30d |
| Jul 30, 2024 | Quarterly ↗ | Jun 30, 2024 | 30d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Feb 22, 2024 | Annual ↗ | Dec 31, 2023 | 53d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Results ↗ |
| Jul 30, 2026 | Results ↗ |
| Jun 22, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Shareholder vote ↗ |
| May 6, 2026 | Results ↗ |
| Feb 25, 2026 | Results ↗ |
| Jan 15, 2026 | Material agreement · Results · Regulation FD ↗ |
| Nov 5, 2025 | Results ↗ |
| Aug 27, 2025 | Director or officer change · Regulation FD ↗ |
| Jul 29, 2025 | Results ↗ |
| May 30, 2025 | Charter or bylaws · Shareholder vote ↗ |
| Apr 23, 2025 | Results ↗ |